Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression.","authors":"Luis E Aguirre, Somedeb Ball, Akriti Jain, Najla Al Ali, David A Sallman, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, Rami S Komrokji","doi":"10.1016/j.clml.2025.03.016","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.016","url":null,"abstract":"<p><strong>Background: </strong>Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder characterized by features of myeloproliferation and myelodysplasia. Various prognostic models incorporate clinical, cytogenetic, and molecular factors to assess risk and guide treatment decisions. However, there has been limited exploration of a subset of patients exhibiting more indolent disease behavior. Due to the significant heterogeneity in disease biology, clonal architecture, clinical presentation, and outcomes, identifying key markers is essential for predicting which patients may present with indolent disease and for recognizing those at greater risk of progression who may require early intervention.</p><p><strong>Patients and methods: </strong>We analyzed baseline clinical and molecular parameters in 656 CMML patients, stratifying them into 2 groups: those observed for ≥ 3 years (indolent CMML) and those needing treatment within that period.</p><p><strong>Results: </strong>14% of CMML patients exhibited indolent disease, correlating with superior outcomes (mOS: 78.5 months vs. 25 months in nonindolent cases). Indolent disease was associated with higher hemoglobin and platelet counts, JAK2 mutations, and fewer cytopenias. In contrast, features indicating the need for earlier treatment included leukocytosis, elevated lymphocyte/monocyte counts, higher percentage of circulating immature cells/blasts, increased marrow cellularity/blasts, and NRAS, ASXL1, and RUNX1 mutations. Changes in the M:E ratio, the presence of abnormally localized immature precursors (ALIP) and gain of mutations reflecting clonal evolution indicated clinical decline and need for timely treatment initiation.</p><p><strong>Conclusion: </strong>A small proportion of CMML patients exhibit indolent features linked to better outcomes, contrasting with markers indicating earlier treatment initiation, which are associated with increased risk of progression; recognizing these markers aids in predicting disease aggressiveness.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical Practice.","authors":"Sophia S Li, Anita D'Souza, Suzanne Lentzsch, Faiza Zafar, Irina Pivneva, Talissa Watson, Annie Guerin, Shaji Kumar","doi":"10.1016/j.clml.2025.03.012","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.012","url":null,"abstract":"<p><strong>Background: </strong>This study described real-world treatment patterns and outcomes in patients with systemic light chain (AL) amyloidosis in the United States (US).</p><p><strong>Methods: </strong>De-identified chart review data were obtained from 117 adult patients diagnosed with systemic AL amyloidosis (01/01/2014-12/31/2021) who initiated 1 L treatment, outside of a clinical trial setting, on or after January 1, 2014, and received ≥ 1 treatment at a US medical center.</p><p><strong>Results: </strong>Among patients, (median age: 63.2 years; female: 50.4%; White: 73.5%; Black/African American: 14.5%), most patients received 2 or more lines of treatment (62.4%) with 30.8% receiving 2 lines of treatment, predominantly cyclophosphamide, bortezomib, and dexamethasone (CyBorD)-, daratumumab-, and dexamethasone-based regimens. In first-line, one third of patients had hematologic response (complete response [CR]: 31.6%; very good partial response (29.1%); for later lines, CR rates tended to decrease. By 57.5 months, ≥60% of patients were still alive (Kaplan-Meier rates - 12 months: 92.0%; 24 months: 84.4%). Median progression-free survival (41.4 months), event-free survival (24.4 months), and time to next treatment (43.2 months) were unexpectedly longest in second line.</p><p><strong>Conclusions: </strong>The study demonstrated that there was heterogeneity in the treatment of AL amyloidosis, and patients who receive treatment can survive for several years after diagnosis without progression.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies.","authors":"Philippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, Maria Esther Gonzalez Garcia, Britta Besemer, Marta Sonia Gonzalez Perez, Mohamad Mohty, Joanne Lindsey-Hill, Suriya Kirkpatrick, Michel Delforge, Emanuele Angelucci, Francesco Di Raimondo, Ravi Vij, Margaret Doyle, Kathleen Gray, Claire Albrecht, Vadim Strulev, Imène Haddad, Silva Koskinen, Lorenzo Acciarri, Jozefien Buyze, Katja Weisel","doi":"10.1016/j.clml.2025.03.014","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.014","url":null,"abstract":"<p><strong>Background: </strong>Patients with relapsed/refractory multiple myeloma (RRMM) who develop extramedullary disease (EMD) generally have a poor prognosis, highlighting the urgent need for new therapies. We report effectiveness outcomes and safety in patients with and without EMD from the pooled analysis of LocoMMotion and MoMMent.</p><p><strong>Methods: </strong>LocoMMotion and MoMMent-1 are prospective, noninterventional, consecutive studies assessing the evolving standard of care from 20192022 in patients with triple-class exposed RRMM.</p><p><strong>Results: </strong>Of 302 patients, 29 had EMD per investigator discretion and only 15 patients were assessed as having true extramedullary plasmacytoma (EMP; defined as patients with ≥1 EMP lesion) by the response review committee. The 29 EMD patients received 21 unique regimens (most commonly chemotherapy-based regimens). Of the 29 patients with EMD, overall response rate (ORR) was 24.1%, median progression-free survival (PFS) was 2.66 months, median overall survival (OS) was 7.16 months, and median time to next treatment (TTNT) was 3.09 months. All responses were lower (ORR) and shorter (median PFS, OS, and TTNT) in patients with EMD vs patients without EMD. Nineteen (65.5%) patients with EMD received ≥1 subsequent lines of therapy. Of those, two (10.5%) patients received bispecific antibodies and achieved a partial response or better; three (15.8%) patients received antibody-drug conjugates (responses were unknown or not determined at data cut-off), and no patients received chimeric antigen receptorT cell therapy.</p><p><strong>Conclusions: </strong>These results demonstrate the urgent need for more effective novel therapies for patients with EMD and highlight the need to use clear definitions of EMD and EMD response criteria for clinical trials.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18).","authors":"Diane Habib, Elias Jabbour, Alex Bataller, Koji Sasaki, Guilin Tang, Sanam Loghavi, Shaoying Li, Jayastu Senapati, Nicholas J Short, Nitin Jain, Hagop Kantarjian, Fadi G Haddad","doi":"10.1016/j.clml.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.010","url":null,"abstract":"<p><strong>Introduction: </strong>The (14;18)(q32;q21) chromosomal translocation leading to IGH::BCL2 rearrangement, has been rarely described in B-cell acute lymphoblastic leukemia (B-ALL), mainly in association with MYC rearrangement. The outcome of B-ALL harboring t(14;18)(q32;q21) without MYC rearrangement remains unknown.</p><p><strong>Methods: </strong>We retrospectively reviewed 2778 cases of B-ALL treated at our institution and identified those harboring a t(14;18)(q32;q21) by karyotype. Cases with concomitant MYC rearrangement and cases of lymphoma were excluded. Three patients with no MYC rearrangement by karyotype but without further confirmation by Fluorescence In Situ Hybridization (FISH), were included.</p><p><strong>Results: </strong>Five patients were included in this analysis, with a median age of 35 years (range, 19-58); 1 patient had central nervous system involvement at diagnosis. Induction therapy consisted of hyper-CVAD in 3 patients, hyper-CVAD with inotuzumab ozogamicin in 1 patient, and asparaginase-based regimen in 1 patient. Four patients (80%) responded, with a median duration of response of 12.9 months (range, 5.1-32.9); 1 patient had primary refractory disease. None of the patients proceeded to an allogeneic hematopoietic stem cell transplantation (HSCT). Four patients received salvage chemotherapy and eventually progressed and died. One patient received salvage therapy with subcutaneous blinatumomab and achieved complete remission with negative measurable residual disease (MRD) by next-generation sequencing (NGS) after 3 courses of therapy. After a median follow-up of 13.4 months, the 2-year event-free survival and overall survival rates were 20% and 25%, respectively.</p><p><strong>Conclusion: </strong>The outcome of B-ALL with t(14;18)(q32;q21) is poor. Incorporating immune-therapies, chimeric antigen receptor (CAR)-T cell therapy, with or without HSCT, into the treatment regimens, might further improve outcomes.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Adolescent LBCL Patients Treated With Adult Type Chemotherapy: A Single Center Experience.","authors":"Riad El Fakih, Taimoor Hussain, Oudai Sahwan, Ghaith Meir, Abdulwahab A Albabtain, Saud Alhayli, Abdullah Alamer, Mhd Anas Alsibai, Shamayel Mohammed, Ali Nasser, Muhammad Shahzad Rauf, Haifa Abdulrahman Alsuwaine, Irfan Maghfoor, Saad Akhtar, Alfadel Alshaibani, Walid Rasheed, Mahmoud Aljurf","doi":"10.1016/j.clml.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.009","url":null,"abstract":"<p><strong>Background: </strong>Lymphoma is the most common cancer in adolescents. Outcome disparities based on the locus of care are increasingly recognized in this age group.</p><p><strong>Materials and methods: </strong>We report outcomes of LBCL patients between 14 and 21 who were treated at an adult center using adult type chemotherapy.</p><p><strong>Results: </strong>Sixty-four patients, median age 19 were analyzed. 82.8% were DLBCL, 17.2% were PMBCL; 21.9% stage I, 31.3% stage II, 7.8% stage III, and 39 % stage IV; 18.8% \"very good\", 62.5% \"good\" and 18.8% \"poor\" RIPI score. The median follow-up period was 68.8 months. The 5 years OS was 94.3%, and the 5 years EFS was 78.3%. High RIPI patients had a worse OS. High RIPI, B symptoms, ABC cell of origin and PMBCL had worse EFS.</p><p><strong>Conclusion: </strong>Pediatric protocol use should be restricted to patients at higher risk of events rather than to all these patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Atypical Chronic Myeloid Leukemia: Pathogenesis, Diagnostic Challenges and Therapeutic Strategies.","authors":"Alessandro Costa, Massimo Breccia","doi":"10.1016/j.clml.2025.03.007","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.007","url":null,"abstract":"<p><p>Atypical chronic myeloid leukemia (aCML) is a rare and challenging clonal hematopoietic disorder within the myelodysplastic/myeloproliferative neoplasm (MDS/MPN) spectrum. Over the past two decades, substantial progress has been made in understanding the genetic mechanisms driving aCML, revealing a complex and heterogeneous mutational landscape. Key ancestral mutations, such as ASXL1 and ETNK1, have been identified, providing a foundation for the pathogenesis and for the possible emergence of secondary abnormalities, particularly in epigenetic regulation (eg, SETBP1), and in splicing process (eg, SRSF2). These molecular insights have been integrated into current diagnostic classifications, refining disease characterization and offering potential targets for precision therapies. Despite these advances, significant clinical challenges persist due to the disease's rarity and the lack of randomized clinical trials. Therapeutic strategies remain inadequately defined, with allogeneic stem cell transplantation being the only curative option. This review provides an overview of the molecular, clinical, and therapeutic information that may pave the way for essential advancements in the proper management of this disease.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing Two Decades of Leukemia Mortality in the U.S. (1999-2020).","authors":"Nouman Aziz, Waseem Nabi, Muzamil Khan, Abu Huraira Bin Gulzar, Shree Rath, Asad Ali Ahmed Cheema, Mirza Ammar Arshad, Fatima Hussain, Abraham Titus, Amar Lal, Faiz Anwar","doi":"10.1016/j.clml.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.006","url":null,"abstract":"<p><strong>Background: </strong>Leukemia is a hematologic malignancy with varying incidence and outcomes influenced by demographic and geographic factors. Understanding mortality trends and disparities is essential for guiding public health policy.</p><p><strong>Objective: </strong>To analyze leukemia mortality trends in the U.S. from 1999 to 2020, focusing on age-adjusted mortality rates (AAMRs), disparities, and geographic patterns.</p><p><strong>Methods: </strong>Data from the CDC WONDER database were analyzed, covering leukemia-related deaths (ICD-10 codes C91-C95). Age groups were stratified into < 45 and ≥ 45 years. Joinpoint regression models estimated annual percentage changes (APCs). Data were examined by demographics, census regions, and urbanization levels.</p><p><strong>Results: </strong>AAMRs for individuals ≥ 45 years declined by an APC of -0.90% but increased slightly from 2018 to 2020. Males, non-Hispanic Whites, and rural populations exhibited higher AAMRs. Among individuals < 45 years old, AAMRs consistently declined with minimal disparities. Acute myeloid leukemia was predominant among older adults, while acute lymphoblastic leukemia affected younger populations.</p><p><strong>Conclusion: </strong>Despite overall declines in leukemia mortality, persistent disparities across age, gender, and geographic regions highlight inequities in healthcare access. Strategic interventions are required to address these gaps and enhance leukemia care nationwide.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.","authors":"Hetty E Carraway, Andrew M Brunner, Catherine E Lai, Marlise R Luskin, Jae Park, Alexander E Perl, Eytan M Stein, Eunice S Wang, Amer M Zeidan, Joshua F Zeidner, Rami Komrokji","doi":"10.1016/j.clml.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.005","url":null,"abstract":"<p><strong>Purpose: </strong>The management of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have evolved substantially in recent years with the development of targeted therapies and novel nontargeted approaches. However, many questions remain about how to best use current therapies, and there is a large unmet need for effective therapies, particularly for patients with higher-risk MDS, AML, and those with MDS/AML relapsed/refractory (R/R) to prior therapy.</p><p><strong>Methods and results: </strong>A panel of experts was assembled to discuss current controversies and unanswered questions in the care of patients with MDS and AML. Workshop topics included: molecular testing and new classification systems, clonal hematopoiesis, treatment of MDS (lower-risk and higher-risk), frontline treatment of AML, treatment of special populations, treatment of R/R AML, and novel approaches.</p><p><strong>Conclusions: </strong>We identified many areas of ongoing controversy in the diagnosis and management of MDS and AML related to classification and risk assessment, treatment selection, sequencing of therapies, and monitoring of responses. Many clinical trials are ongoing to further improve outcomes for patients with MDS and AML, and we noted potential areas of debate related to study design, selection of endpoints, and assessment of responses. The controversies and gaps in knowledge identified by this panel will inform a follow-up conference in 2025 that will employ a modified Delphi method with a goal of developing and publishing formal consensus recommendations that can provide actionable guidance to clinicians in practice.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143787869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma.","authors":"Ajai Chari, Susan Bal, Sikander Ailawadhi, Amrita Krishnan, Krina K Patel, Jesus G Berdeja, Alfred Garfall, Natalie Callander, Rahul Banerjee, Melissa Alsina, Ajay K Nooka, Binod Dhakal, Cristina Gasparetto, Caitlin Costello","doi":"10.1016/j.clml.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.clml.2025.03.008","url":null,"abstract":"<p><strong>Purpose: </strong>The management of multiple myeloma (MM) is becoming increasingly more complex. The approval of novel treatment approaches provides much-needed opportunities but also raises questions and controversies about how to optimally sequence therapies and select treatments for individual patients.</p><p><strong>Methods and results: </strong>A panel of experts assembled to discuss current controversies in the care of patients with MM across the disease continuum. Workshop topics included: management of smoldering MM; treatment selection for transplant-eligible and transplant-ineligible patients; risk assessment and the possibility of risk-adapted treatment; use of measurable residual disease (MRD) as a clinical trial end point and to guide treatment decisions; management of early relapse; management of triple class-refractory MM; treatment sequencing; and novel therapies.</p><p><strong>Conclusion: </strong>Many controversies remain regarding the management of patients with MM related to risk assessment, treatment selection and sequencing, and the optimal use of current therapies while balancing efficacy, toxicity, patient considerations, and treatment logistics. Ongoing research efforts are needed to further define the optimal use of current therapies and to develop more efficacious therapies for all patients and for particular subset populations with unmet need.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Monoclonal Gammopathy of Undetermined Significance-Like (MGUS-like) Classifier Stratifies Prognosis in Multiple Myeloma: Results from Real-World Data in Chinese Population","authors":"Wenqiang Yan ,&nbsp;Jieqiong Zhou ,&nbsp;Yuntong Liu ,&nbsp;Jingyu Xu ,&nbsp;Jian Cui ,&nbsp;Chenxing Du ,&nbsp;Shuaishuai Zhang ,&nbsp;Rui Lv ,&nbsp;Weiwei Sui ,&nbsp;Shuhui Deng ,&nbsp;Yan Xu ,&nbsp;Shuhua Yi ,&nbsp;Dehui Zou ,&nbsp;Mu Hao ,&nbsp;Lugui Qiu ,&nbsp;Gang An","doi":"10.1016/j.clml.2025.03.002","DOIUrl":"10.1016/j.clml.2025.03.002","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages e452-e456.e4"},"PeriodicalIF":2.7,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}